“…Other viral RNAs such as the hepatitis C virus internal ribosomal entry site (HCV IRES) and Influenza A have been focus of several targeting studies (Dibrov, et al, 2014; Lee, et al, 2014). Recently, several small molecules have been designed to target nucleotide repeat expansions including fragile X-associated tremor ataxia syndrome (FXTAS; CGG) (Yang, et al, 2016), myotonic dystrophy type 1 (DM1; CUG) (Gareiss, et al, 2008; Jahromi, et al, 2013; Pushechnikov, et al, 2009), myotonic dystrophy type 2 (DM2; CCUG) (Childs-Disney, et al, 2014), Huntington’s disease (HD; CAG) (Kumar, et al, 2012), and frontotemporal dementia and amyotrophic lateral sclerosis (c9FTD/ALD; G 4 C 2 ) (Su, et al, 2014). A salient question is if small molecules that target non-coding RNAs can be identified and developed into medicines or chemical probes.…”